Dynamic Monitoring of Plasma ctDNA for Prognostic Assessment in Patients With B-Cell Non-Hodgkin Lymphoma

For patients with newly diagnosed or relapsed/metastatic B-cell non-Hodgkin lymphoma following first-line treatment, peripheral blood samples are collected before treatment and at various treatment time points to monitor circulating tumor DNA (ctDNA), aiming to investigate the correlation between dynamic ctDNA changes and patient prognosis.

NCT Number	NCT07480837
Lead Sponsor	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions	B-Cell Non-Hodgkin Lymphoma
Enrollment	60 participants
Start Date	2026-01-01
Primary Completion	2029-01-01 (estimated)
Study Completion	2031-01-01 (estimated)
Updated on ClinicalTrials.gov	2026-03-18